Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | ENPP2 | Q13822 | 14/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18012398 | 1.00 | LMNA (0.73) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL945578 | 0.84 | POLB (0.61) | LMNATP53MEN1KMT2AMAPT | |
| SCHEMBL19771388 | 0.81 | LMNA (0.82) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL30100222 | 0.79 | ENPP2 (1.00) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL18012519 | 0.79 | ENPP2 (1.00) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL30100208 | 0.79 | ENPP2 (0.82) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL18012515 | 0.79 | ENPP2 (0.82) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL18012509 | 0.79 | ENPP2 (1.00) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL30100225 | 0.79 | ENPP2 (1.00) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL17966957 | 0.78 | ENPP2 (0.80) | LMNAENPP2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-11453666-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453666-B2 | Autotaxin inhibitory compounds | ENPP2, RNASE1, ATXN10 | LMNA 793/4885ENPP2 1/4885TP53 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.